Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.

Fernández-Esgueva, Marta; López-Calleja, Ana Isabel; Mulet, Xavier; Fraile-Ribot, Pablo A; Cabot, Gabriel; Huarte, Rafael; Rezusta, Antonio; Oliver, Antonio

doi:10.1016/j.eimc.2020.01.017

Record: found
Abstract: found
Article: not found

Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.

Author(s): Marta Fernández-Esgueva ¹ , Ana Isabel López-Calleja ² , Xavier Mulet ³ , Pablo A Fraile-Ribot ³ , Gabriel Cabot ³ , Rafael Huarte ⁴ , Antonio Rezusta ¹ , Antonio Oliver ³

Publication date (Electronic): Dec 2020

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Publisher: Elsevier BV

Keywords: AmpC beta-lactamase, Betalactamasa AmpC, Ceftolozane/tazobactam, Ceftolozano/tazobactam, Emerging resistance, Pseudomonas aeruginosa, Resistencia emergente

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

We characterized AmpC β-lactamase mutations that resulted in ceftolozane/tazobactam resistance in extensively drug-resistant (XDR) Pseudomonas aeruginosa isolates recovered from patients treated with this agent from June 2016 to December 2018.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Enferm Infecc Microbiol Clin (Engl Ed)

Title: Enfermedades infecciosas y microbiologia clinica (English ed.)

Publisher: Elsevier BV

ISSN (Electronic): 2529-993X

ISSN (Print): 2529-993X

Publication date (Electronic): Dec 2020

Volume: 38

Issue: 10

Affiliations

[1 ] Servicio de Microbiología, Hospital Universitario Miguel Servet, IIS Aragón, Zaragoza, Spain.

[2 ] Servicio de Microbiología, Hospital Universitario Miguel Servet, IIS Aragón, Zaragoza, Spain. Electronic address: ailopezc@aragon.es.

[3 ] Servicio de Microbiología y Unidad de Investigación, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Illes Balears (IdISBa), Palma de Mallorca, Spain.

[4 ] Servicio de Farmacia, Hospital Universitario Miguel Servet, IIS Aragón, Zaragoza, Spain.

Article

Publisher Item ID: S0213-005X(20)30024-0

DOI: 10.1016/j.eimc.2020.01.017

PubMed ID: 32143893

SO-VID: 5949186c-3fcf-4aa8-b1e6-a24efece4e8d

History

Keywords: AmpC beta-lactamase,Betalactamasa AmpC,Ceftolozane/tazobactam,Ceftolozano/tazobactam,Emerging resistance,Pseudomonas aeruginosa,Resistencia emergente

Data availability:

Keywords: AmpC beta-lactamase, Betalactamasa AmpC, Ceftolozane/tazobactam, Ceftolozano/tazobactam, Emerging resistance, Pseudomonas aeruginosa, Resistencia emergente

Characterization of AmpC β-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy.

Read this article at

Abstract

Related collections

Neuropharmacology and Therapy

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 144

Cited by 6